Trials / Completed
CompletedNCT01149382
Immune Response to Influenza Vaccine in Islet Cell Transplant Recipients
Humoral Immune Response To Influenza Vaccine In Islet Cell In Transplant Recipients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 61 (actual)
- Sponsor
- University of Alberta · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for organ transplant patients, studies have shown that the standard inactivated influenza vaccine has poor immunogenicity in this population. The investigators plan to test the humoral response to vaccination and look at HLA upregulation
Detailed description
OBJECTIVE AND HYPOTHESIS * To test the specific humoral response of the influenza vaccine after islet cell transplantation * To test the production of HLA alloantibodies after vaccination.
Conditions
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2011-08-01
- Completion
- 2011-12-01
- First posted
- 2010-06-23
- Last updated
- 2012-08-21
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01149382. Inclusion in this directory is not an endorsement.